Every 8-K that CVS Health Corporation (CVS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CVS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CVS filings page.
CVS Health Corporation reported changes to its Board of Directors. On August 13, 2026, Larry M. Robbins resigned from the Board, effective immediately, with the company stating his departure did not result from any disagreement over operations, policies or practices. On August 17, 2026, the Board appointed Teresa Heitsenrether, Executive Vice President and Chief Data & Analytics Officer of JPMorgan Chase & Co., to join the Board effective November 18, 2026. She was determined to be independent under New York Stock Exchange rules and the company’s Corporate Governance Guidelines and will receive compensation consistent with other non‑employee directors, prorated to reflect her start date.
CVS Health highlighted its scale as of June 30, 2026, including approximately 9,000 retail pharmacy locations, more than 1,000 walk‑in and primary care clinics, a pharmacy benefits manager with about 87 million plan members, and health insurance products and services serving an estimated 37 million people.
CVS Health reported strong results for the three months ended June 30, 2026. Total revenues were $106.1 billion, up 7.3% year-over-year. GAAP diluted EPS rose to $2.31 from $0.80, and Adjusted EPS increased to $2.58 from $1.81. Operating income was $4.7 billion, up 97.5%, with adjusted operating income up 35.4% to $5.2 billion. Year-to-date cash flow from operations reached $10.6 billion.
In the Health Care Benefits segment, revenues grew 3.5% and adjusted operating income increased 85.5% to $2.4 billion, while the medical benefit ratio improved to 87.4%. Health Services revenues rose 11.5% to $51.8 billion with 10.0% higher adjusted operating income, and Pharmacy & Consumer Wellness revenues inched up 0.7% as adjusted operating income grew 10.2% and prescriptions filled rose 4.3%. CVS raised its full-year 2026 guidance, increasing GAAP diluted EPS to $6.84–$7.04, Adjusted EPS to $7.90–$8.10, and cash flow from operations to at least $11.5 billion. The company also highlighted GLP-1 support initiatives and deployment of agentic AI tools across call centers and claims processing.
CVS Health Corporation reported results from its May 14, 2026 Annual Meeting of Stockholders. Shareholders approved the new 2026 Incentive Compensation Plan, which will govern awards granted after May 14, 2026 and replaces the expiring 2017 plan.
All 13 director nominees were elected for one-year terms. Shareholders also ratified Ernst & Young LLP as independent auditor for 2026 and approved, on an advisory basis, executive compensation as described in the proxy statement. A stockholder proposal to reduce the threshold for acting by written consent did not pass. A quorum was present, with 1,142,802,406 common shares represented.
CVS Health Corporation reported strong first quarter 2026 results and raised its full-year outlook. Total revenues rose to $100.4 billion, up 6.2% from $94.6 billion a year earlier. GAAP diluted EPS increased to $2.30 from $1.41, while Adjusted EPS grew to $2.57 from $2.25, helped largely by much higher adjusted operating income in the Health Care Benefits segment and the absence of prior-year litigation and divestiture charges.
For 2026, CVS raised its GAAP diluted EPS guidance to a range of $6.24–$6.44 and Adjusted EPS to $7.30–$7.50. The company also increased its cash flow from operations guidance to at least $9.5 billion. Management highlighted improved performance in Health Care Benefits and contributions from its integrated health services model, while noting a continued cautious stance given elevated cost trends and potential macroeconomic headwinds.
CVS Health Corporation announced that its Board of Directors elected John E. Gallina to the Board, effective March 19, 2026. Gallina is the former Executive Vice President and Chief Financial Officer of Elevance Health, Inc., where he spent nearly 30 years in senior finance and risk roles.
The Board determined that Gallina is an independent director under New York Stock Exchange rules and the company’s Corporate Governance Guidelines. He was also appointed to CVS Health’s Audit Committee and designated an “audit committee financial expert” under SEC rules.
Gallina currently serves on the Board of Arrive AI Inc., where he chairs the audit committee, and holds board roles at two privately held non-profit organizations. His compensation as a non-employee CVS Health director will align with that of other non-employee directors, prorated based on his start date.
CVS Health reported strong 2025 top-line growth but sharply lower GAAP profit due to large one-time charges. Total revenues rose 7.8% to a record $402.1 billion, with fourth-quarter revenue up 8.2% to $105.7 billion.
Full-year GAAP diluted EPS fell to $1.39 from $3.66, mainly driven by a $5.7 billion goodwill impairment in the Health Services segment and about $1.2 billion of legacy litigation charges. By contrast, adjusted EPS increased to $6.75 from $5.42, reflecting stronger underlying operations, especially in Pharmacy & Consumer Wellness. Cash flow from operations was $10.6 billion. For 2026, CVS reaffirmed GAAP EPS guidance of $5.94–$6.14 and adjusted EPS of $7.00–$7.20, but lowered its operating cash flow outlook to at least $9.0 billion from at least $10.0 billion.
CVS Health Corporation furnished information from its 2025 Investor Day, where it discussed strategic priorities and updated its financial outlook. On December 9, 2025, the company issued a press release that revised its full-year 2025 financial guidance and introduced full-year 2026 financial guidance. The press release is attached as Exhibit 99.1 to this report and is incorporated into the Regulation FD disclosure section by reference.
The company notes that this press release and related information are being furnished, not filed, under securities laws, meaning they are not automatically subject to certain liability provisions or incorporated into other securities filings unless specifically referenced.
CVS Health Corporation announced a governance change at the top of its leadership structure. On November 20, 2025, the Board appointed President and Chief Executive Officer J. David Joyner to also serve as Chair of the Board, effective January 1, 2026. After this change takes effect, Michael F. Mahoney will continue as Lead Independent Director, and Roger N. Farah, currently Executive Chair, will remain on the Board as a director. The company also issued a press release describing this appointment, which is filed as an exhibit.
CVS Health Corporation furnished an update on its financial performance. The company announced results for the three months ended September 30, 2025, and made the related press release available as Exhibit 99.1 under Item 2.02.
The materials are furnished, not filed, under the Exchange Act, which means they are not subject to Section 18 liability and are not incorporated by reference unless specifically stated.
CVS Health Corporation reports that its wholly owned indirect subsidiary Omnicare, LLC and certain related entities have voluntarily begun chapter 11 bankruptcy proceedings in the U.S. to address issues arising from recent litigation in the U.S. District Court for the Southern District of New York, where the court imposed what Omnicare describes as excessive monetary damages.
Omnicare plans to use the court-supervised process to handle broader financial challenges in the long-term care pharmacy industry and to consider restructuring options, including a potential standalone restructuring or sale. Omnicare has arranged debtor-in-possession financing with a third party, which, once approved by the court and combined with ongoing operating cash flows, is expected to provide enough liquidity for the Omnicare entities to continue operating while the chapter 11 process proceeds.
CVS Health Corporation filed an 8-K reporting documentation related to a debt offering process. The filing references an Underwriting Agreement dated August 11, 2025 naming Barclays Capital Inc., J.P. Morgan Securities LLC and Wells Fargo Securities, LLC as representatives of the underwriters. The forms of four notes with maturities labeled 2032, 2035, 2055 and 2065 are included as exhibits, along with the opinion and consent of Wachtell, Lipton, Rosen & Katz. The cover page Inline XBRL data is noted as filed. The filing is signed by Brian Newman, Executive Vice President and Chief Financial Officer on August 15, 2025.